Drug Profile
ASC JM.X1
Alternative Names: 2nd generation ARD enhancer - AndroScience Corporation; ASC-JM.X1Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator AndroScience Corporation
- Class Small molecules
- Mechanism of Action Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported X-linked bulbo-spinal atrophy
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in X-linked-bulbo-spinal-atrophy in USA (PO)
- 06 Jul 2016 Preclinical trials in X-linked-bulbo-spinal-atrophy in USA (PO)